Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.35 |
| ▸ | DPP4 | P27487 | 15/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990658 | 1.00 | DPP7 (0.35) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2990654 | 1.00 | DPP7 (0.35) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL27783127 | 1.00 | DPP7 (0.35) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2983471 | 0.93 | DPP4 (0.38) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2981553 | 0.93 | DPP4 (0.38) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2983474 | 0.93 | DPP4 (0.38) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2981617 | 0.91 | HRH3 (0.34) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2981611 | 0.91 | HRH3 (0.34) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2981615 | 0.91 | HRH3 (0.34) | DPP7DPP4DPP8DPP9 | |
| SCHEMBL2985762 | 0.91 | HRH3 (0.34) | DPP7DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267766-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-21 | — | — | US | disclosed |
| US-7776880-B2 | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| CN-101573113-A | Derivatives of pyridine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2009-11-04 | — | — | CN | disclosed |
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2077837-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008037881-A2 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258899-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INMT, IDO1, NQO2 | DPP7 2159/4885DPP4 1913/4885DPP8 1557/4885 |
| US-20100267766-A1 | DERIVATIVES OF PYRROLIZINE, INDOLIZINE AND QUINOLIZINE, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INMT, IDO1, NQO2 | DPP7 2159/4885DPP4 1913/4885DPP8 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.